Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients

Zehra Husain, Gurunanthan Palani, Rafael Cabrera, Aarthee S. Karthikeyan, Sunitha Dhanalakota, Suba Pathmanathan, Gordon Jacobsen, Karthik Ananthasubramaniam

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Regadenoson (REG) is a A2a receptor selective pharmacologic SPECT imaging agent. Its safety in unselected chronic obstructive pulmonary disease (COPD) or asthma (AM) undergoing SPECT imaging has not been well evaluated. We retrospectively identified 228 patients (COPD n = 126 and AM n = 102, Grp 1) undergoing REG SPECT from Jan to Nov 2009 and compared to 1,142 patients without COPD and AM (control, Grp 2). A standard 400 lg REG bolus was used and gated Tc-99 m tetrofosmin SPECT done. Patient demographics, REG SPECT data, side effects, arrhythmia occurrences, and any exacerbation of COPD or AM leading to treatment, hospitalization or death were evaluated. The side effect profile of Grp 1 was also compared to a historical cohort who underwent intravenous dipyridamole thallium-201 imaging and adenosine SPECT. Both groups were comparable with regards to baseline characteristics. There was 0% incidence of clinical exacerbation of COPD or AM after REG. COPD patients had more non-significant arrhythmias (58.3% vs. Grp 2, 43%, P = 0.004). There was 0% incidence of any atrio-ventricular block and only 2 instances of brief supraventricular tachycardia. When compared to the historical cohort of COPD who underwent IV dipyridamole thallium imaging, COPD in Grp 1, had more dyspnea and flushing and when compared to COPD/AM patients who underwent adenosine SPECT, Grp 1 pts had more of flushing and headache (24.9% vs. 2.8%, P =\0.001) but less of bronchospasm (1.3% vs. 6.9%, P = 0.022) and AV block (0% vs. 4.2%, P = 0.014). REG SPECT can be safely performed in COPD and AM population.

Original languageEnglish (US)
Pages (from-to)1841-1849
Number of pages9
JournalInternational Journal of Cardiovascular Imaging
Volume28
Issue number7
DOIs
StatePublished - Oct 1 2012

Fingerprint

Myocardial Perfusion Imaging
Chronic Obstructive Pulmonary Disease
Single-Photon Emission-Computed Tomography
Asthma
Hemodynamics
Safety
Dipyridamole
Thallium
Adenosine
Cardiac Arrhythmias
regadenoson
Bronchial Spasm
Supraventricular Tachycardia
Atrioventricular Block
Incidence
Dyspnea
Headache
Hospitalization
Demography

Keywords

  • Asthma
  • Bronchospasm
  • Chronic obstructive pulmonary disease
  • Regadenoson
  • Side effects
  • Single photon emission computed tomography

Cite this

Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. / Husain, Zehra; Palani, Gurunanthan; Cabrera, Rafael; Karthikeyan, Aarthee S.; Dhanalakota, Sunitha; Pathmanathan, Suba; Jacobsen, Gordon; Ananthasubramaniam, Karthik.

In: International Journal of Cardiovascular Imaging, Vol. 28, No. 7, 01.10.2012, p. 1841-1849.

Research output: Contribution to journalArticle

Husain, Zehra ; Palani, Gurunanthan ; Cabrera, Rafael ; Karthikeyan, Aarthee S. ; Dhanalakota, Sunitha ; Pathmanathan, Suba ; Jacobsen, Gordon ; Ananthasubramaniam, Karthik. / Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. In: International Journal of Cardiovascular Imaging. 2012 ; Vol. 28, No. 7. pp. 1841-1849.
@article{a15700c9ac014df59358da276463a2f1,
title = "Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients",
abstract = "Regadenoson (REG) is a A2a receptor selective pharmacologic SPECT imaging agent. Its safety in unselected chronic obstructive pulmonary disease (COPD) or asthma (AM) undergoing SPECT imaging has not been well evaluated. We retrospectively identified 228 patients (COPD n = 126 and AM n = 102, Grp 1) undergoing REG SPECT from Jan to Nov 2009 and compared to 1,142 patients without COPD and AM (control, Grp 2). A standard 400 lg REG bolus was used and gated Tc-99 m tetrofosmin SPECT done. Patient demographics, REG SPECT data, side effects, arrhythmia occurrences, and any exacerbation of COPD or AM leading to treatment, hospitalization or death were evaluated. The side effect profile of Grp 1 was also compared to a historical cohort who underwent intravenous dipyridamole thallium-201 imaging and adenosine SPECT. Both groups were comparable with regards to baseline characteristics. There was 0{\%} incidence of clinical exacerbation of COPD or AM after REG. COPD patients had more non-significant arrhythmias (58.3{\%} vs. Grp 2, 43{\%}, P = 0.004). There was 0{\%} incidence of any atrio-ventricular block and only 2 instances of brief supraventricular tachycardia. When compared to the historical cohort of COPD who underwent IV dipyridamole thallium imaging, COPD in Grp 1, had more dyspnea and flushing and when compared to COPD/AM patients who underwent adenosine SPECT, Grp 1 pts had more of flushing and headache (24.9{\%} vs. 2.8{\%}, P =\0.001) but less of bronchospasm (1.3{\%} vs. 6.9{\%}, P = 0.022) and AV block (0{\%} vs. 4.2{\%}, P = 0.014). REG SPECT can be safely performed in COPD and AM population.",
keywords = "Asthma, Bronchospasm, Chronic obstructive pulmonary disease, Regadenoson, Side effects, Single photon emission computed tomography",
author = "Zehra Husain and Gurunanthan Palani and Rafael Cabrera and Karthikeyan, {Aarthee S.} and Sunitha Dhanalakota and Suba Pathmanathan and Gordon Jacobsen and Karthik Ananthasubramaniam",
year = "2012",
month = "10",
day = "1",
doi = "10.1007/s10554-011-0003-3",
language = "English (US)",
volume = "28",
pages = "1841--1849",
journal = "International Journal of Cardiovascular Imaging",
issn = "1569-5794",
publisher = "Springer Netherlands",
number = "7",

}

TY - JOUR

T1 - Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients

AU - Husain, Zehra

AU - Palani, Gurunanthan

AU - Cabrera, Rafael

AU - Karthikeyan, Aarthee S.

AU - Dhanalakota, Sunitha

AU - Pathmanathan, Suba

AU - Jacobsen, Gordon

AU - Ananthasubramaniam, Karthik

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Regadenoson (REG) is a A2a receptor selective pharmacologic SPECT imaging agent. Its safety in unselected chronic obstructive pulmonary disease (COPD) or asthma (AM) undergoing SPECT imaging has not been well evaluated. We retrospectively identified 228 patients (COPD n = 126 and AM n = 102, Grp 1) undergoing REG SPECT from Jan to Nov 2009 and compared to 1,142 patients without COPD and AM (control, Grp 2). A standard 400 lg REG bolus was used and gated Tc-99 m tetrofosmin SPECT done. Patient demographics, REG SPECT data, side effects, arrhythmia occurrences, and any exacerbation of COPD or AM leading to treatment, hospitalization or death were evaluated. The side effect profile of Grp 1 was also compared to a historical cohort who underwent intravenous dipyridamole thallium-201 imaging and adenosine SPECT. Both groups were comparable with regards to baseline characteristics. There was 0% incidence of clinical exacerbation of COPD or AM after REG. COPD patients had more non-significant arrhythmias (58.3% vs. Grp 2, 43%, P = 0.004). There was 0% incidence of any atrio-ventricular block and only 2 instances of brief supraventricular tachycardia. When compared to the historical cohort of COPD who underwent IV dipyridamole thallium imaging, COPD in Grp 1, had more dyspnea and flushing and when compared to COPD/AM patients who underwent adenosine SPECT, Grp 1 pts had more of flushing and headache (24.9% vs. 2.8%, P =\0.001) but less of bronchospasm (1.3% vs. 6.9%, P = 0.022) and AV block (0% vs. 4.2%, P = 0.014). REG SPECT can be safely performed in COPD and AM population.

AB - Regadenoson (REG) is a A2a receptor selective pharmacologic SPECT imaging agent. Its safety in unselected chronic obstructive pulmonary disease (COPD) or asthma (AM) undergoing SPECT imaging has not been well evaluated. We retrospectively identified 228 patients (COPD n = 126 and AM n = 102, Grp 1) undergoing REG SPECT from Jan to Nov 2009 and compared to 1,142 patients without COPD and AM (control, Grp 2). A standard 400 lg REG bolus was used and gated Tc-99 m tetrofosmin SPECT done. Patient demographics, REG SPECT data, side effects, arrhythmia occurrences, and any exacerbation of COPD or AM leading to treatment, hospitalization or death were evaluated. The side effect profile of Grp 1 was also compared to a historical cohort who underwent intravenous dipyridamole thallium-201 imaging and adenosine SPECT. Both groups were comparable with regards to baseline characteristics. There was 0% incidence of clinical exacerbation of COPD or AM after REG. COPD patients had more non-significant arrhythmias (58.3% vs. Grp 2, 43%, P = 0.004). There was 0% incidence of any atrio-ventricular block and only 2 instances of brief supraventricular tachycardia. When compared to the historical cohort of COPD who underwent IV dipyridamole thallium imaging, COPD in Grp 1, had more dyspnea and flushing and when compared to COPD/AM patients who underwent adenosine SPECT, Grp 1 pts had more of flushing and headache (24.9% vs. 2.8%, P =\0.001) but less of bronchospasm (1.3% vs. 6.9%, P = 0.022) and AV block (0% vs. 4.2%, P = 0.014). REG SPECT can be safely performed in COPD and AM population.

KW - Asthma

KW - Bronchospasm

KW - Chronic obstructive pulmonary disease

KW - Regadenoson

KW - Side effects

KW - Single photon emission computed tomography

UR - http://www.scopus.com/inward/record.url?scp=84870410331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870410331&partnerID=8YFLogxK

U2 - 10.1007/s10554-011-0003-3

DO - 10.1007/s10554-011-0003-3

M3 - Article

C2 - 22200931

AN - SCOPUS:84870410331

VL - 28

SP - 1841

EP - 1849

JO - International Journal of Cardiovascular Imaging

JF - International Journal of Cardiovascular Imaging

SN - 1569-5794

IS - 7

ER -